Guide Therapeutics, Inc. has patented technologies to test thousands of chemically distinct nanoparticles in vivo. This enables them to identify simple, scalable, and clinically relevant nanoparticles that target new cell types efficiently and safely.
This technology utilizes DNA barcodes, which are DNA sequences that are rationally designed to act as molecular tags for specific nanoparticles. Tagging individual nanoparticles with barcodes and injecting many in parallel industrializes nanoparticle discovery, allowing Guide to perform thousands of nanoparticle experiments simultaneously.
Guide has developed methods to perform thousands of in vivo drug delivery experiments at once. Each method is tailored to the payload: mRNA delivery is studied using mRNA, and siRNA delivery is studied using siRNA. Their approach, which has led to awards including Top 10 Emerging Technologies in the World by the World Economic Forum, allows them to pursue gene therapies in cells that cannot be targeted otherwise.
